Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03127631 · ClinicalTrials.gov registry record · NA

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

A NA study of Prostate Cancer and Cardiovascular Disease, sponsored by McMaster University.

Recruiting
Registry status
NA
Development phase
6,000
Enrollment target
20
Study locations

NCT03127631 is a NA study of Prostate Cancer and Cardiovascular Disease that is actively recruiting participants, run by McMaster University. The registered enrollment target is 6,000 participants, above the 600-participant average among 735 other Prostate Cancer trials with a reported enrollment target (900% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03127631, a NA study of Prostate Cancer and Cardiovascular Disease, is actively recruiting participants, sponsored by McMaster University.

RECRUITING
Registry status
NA
Development phase
6,000 participants
Enrollment target
20
Study locations

Study Summary

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

Conditions Studied

Prostate Cancer Cardiovascular Disease

Interventions

  • BEHAVIORAL Exercise
  • BEHAVIORAL Nutrition
  • BEHAVIORAL Smoking cessation
  • DRUG Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
  • DRUG ACE inhibitor

Study Locations (20)

Rio Grande do Sul

  • Hospital de Caridade de Ijuí - Ijuí
  • Hospital de Clínicas de Porto Alegre - Porto Alegre
  • Irmandade Da Santa Casa De Misericórdia De Porto Alegre - Porto Alegre
  • Hospital Mae de Deus - Porto Alegre

Paraná

  • Sociedade Hospitalar Angelina Caron - Campina Grande do Sul
  • Nucleo de Pesquisa Clinica Hospital do Rocio - Campo Largo
  • Centro Médico São Francisco - Curitiba

São Paulo

  • Hospital Municipal de Barueri - Barueri
  • Faculdade de Medicina da Universidade Estadual Paulista - Campus de Botucatu - UNESP - Botucatu
  • Hospital Universitário São Francisco na Providência de Deus - Bragança Paulista

South Australia

  • Royal Adelaide Hospital - Adelaide
  • Flinders Medical Center - Adelaide

Minas Gerais

  • Hospital Felício Rocho - Belo Horizonte
  • Universidade Federal do Triângulo Mineiro - Uberaba

Georgia

  • Georgia Cancer Center at Augusta University - Augusta

Kansas

  • University of Kansas Medical Center - Kansas City

New South Wales

  • Westmead Hospital - Westmead

Trial Details

FieldValue
Enrollment Target 6,000 participants
Start Date 2015-10-21
Est. Completion 2026-12
Phase NA

Sponsor

McMaster University

31 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03127631

The ClinicalTrials.gov registry entry for NCT03127631 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 600-participant average among 735 other Prostate Cancer trials with a reported enrollment target (900% higher). The listed sponsor is McMaster University, which has 31 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Exercise is the first listed.

NCT03127631 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Rio Grande do Sul, Paraná, São Paulo.

Frequently Asked Questions

What is clinical trial NCT03127631 about?

NCT03127631 is a clinical study titled "A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients". RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

What is the current status of trial NCT03127631?

This trial is currently recruiting. It is a NA study. The enrollment target is 6,000 participants. The study started on 2015-10-21. Estimated completion is 2026-12.

What conditions does trial NCT03127631 study?

This clinical trial studies the following conditions: Prostate Cancer, Cardiovascular Disease.

What interventions are being tested in trial NCT03127631?

The interventions under investigation include: Exercise (BEHAVIORAL), Nutrition (BEHAVIORAL), Smoking cessation (BEHAVIORAL), Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) (DRUG), ACE inhibitor (DRUG).

Who is sponsoring clinical trial NCT03127631?

This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03127631 being conducted?

This trial has 20 study locations across Georgia, Kansas, New South Wales, South Australia, Federal District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Cardiovascular Disease

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.